2 Dec 2009 07:00
Epistem Holdings Plc
2 December 2009
Epistem Plc (LSE: EHP), the rapidly growing UK biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases, announces today that all resolutions at the Annual General Meeting held on 25 November 2009 were passed.
The Company's amended Articles and Associations can be viewed on the Epistem website at http://www.epistem.co.uk/constitutional-documents.asp.
| Epistem Plc | |
| Matthew Walls CEO | +44 (0) 7887 501 998 |
| John Rylands CFO | +44 (0) 161 606 7258 |
| Piper Jaffray Ltd. | |
| Neil Mackison | +44 (0) 20 3142 8700 |
| De Facto Communications | |
| Mike Wort / Anna Dunphy | +44 (0) 20 7861 3838 |
Notes to Editors:
About Epistem
Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.
Genedrive (GDR)